secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kyverna Therapeutics, Inc. (KYTX)
CIK:        0001994702
Form:       8-K
Filed at:   2025-12-18T23:59:59+00:00
Accession:  0001213900-25-123033
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kyverna prices $100M public offering of 13.3M shares at $7.50 per share
-----------------------------------------------------------------------

- Offering of 13,333,333 shares of common stock at $7.50/share; gross proceeds ~$100M.
- Underwriters granted a 30-day option to purchase up to 1,999,999 additional shares at $7.50/share less discounts.
- Net proceeds for general corporate purposes, including R&D, capex, working capital.
- Expected closing on or about December 18, 2025; directors, officers, affiliates subject to lock-up through January 31, 2026.
- Joint book-running managers: J.P. Morgan, Leerink Partners, Morgan Stanley, Wells Fargo Securities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1994702/000121390025123033/0001213900-25-123033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1994702/000121390025123033/ea0270041-8k_kyverna.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-123033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer